Enanta Pharmaceuticals Inc (ENTA): Shareholders' Equity
$64.72M
As of 2025-09-30
$101.07M
As of 2026-06-30
-41.4%
3-year compound annual growth
-32.3%
5-year compound annual growth
-12.1%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $64.72M | -49.8% | 2025-11-19, Balance as of period end |
| 2024-09-30 | $128.81M | -40.6% | 2025-11-19, Balance as of period end |
| 2023-09-30 | $216.74M | -32.6% | 2025-11-19, Balance as of period end |
| 2022-09-30 | $321.33M | -19.6% | 2024-11-27, Balance as of period end |
| 2021-09-30 | $399.43M | -12.3% | 2023-11-22, Balance as of period end |
| 2020-09-30 | $455.58M | -1.5% | 2022-11-23, Balance as of period end |
| 2019-09-30 | $462.49M | +17.5% | 2021-11-24, Balance as of period end |
| 2018-09-30 | $393.68M | +30.5% | 2020-11-25, Balance as of period end |
| 2017-09-30 | $301.68M | +11.8% | 2019-11-27, Balance as of period end |
| 2016-09-30 | $269.94M | +14.3% | 2018-11-29, Balance as of period end |
| 2015-09-30 | $236.16M | +58.9% | 2017-12-11, Balance as of period end |
| 2014-09-30 | $148.65M | +34.6% | 2016-12-09, Balance as of period end |
| 2013-09-30 | $110.47M | n/m | 2015-12-11, Balance as of period end |
| 2012-09-30 | -$115.35M | n/m | 2014-12-11, Balance as of period end |
| 2011-09-30 | -$131.96M | n/a | 2013-12-18, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $64.72M | -49.8% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $59.02M | +28.0% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $49.87M | +119.3% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $174.13M | -57.9% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $305.72M | -34.1% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $346.18M | +73.5% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $36.98M | +13.5% |
| Journey Medical Corp (DERM) | 2025-12-31 | $31.85M | +58.7% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $722.17M | +7.5% |
Compare ENTA, SPRO, FBIO, KURA side by side · Screen every company in Pharmaceutical Preparations ↗